Is maintenance capecitabine indicated for a patient with pT1cN0 triple-negative breast cancer who has completed adjuvant dose-dense doxorubicin/cyclophosphamide followed by paclitaxel (AC-T)?

This patient has received appropriate adjuvant therapy with ddAC- weekly paclitaxel for early-stage node-negative TNBC. The added benefit of capecitabine is unclear. Evidence supporting its use in the adjuvant setting from CREATE-X and EA1131 is largely applicable to patients with residual disease f...